[{"id":"09038cde-7312-4363-a45d-ebec4e051166","acronym":"FusionVAC22_02","url":"https://clinicaltrials.gov/study/NCT06789198","created_at":"2025-02-25T17:54:08.734Z","updated_at":"2025-02-25T17:54:08.734Z","phase":"Phase 1","brief_title":"Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA","source_id_and_acronym":"NCT06789198 - FusionVAC22_02","lead_sponsor":"University Hospital Tuebingen","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA peptide vaccine • Fusion-VAC-XS15"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 11/01/2028","primary_completion_date":" 11/01/2028","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-01-28"},{"id":"0fa8d48e-d40b-4172-a31d-5c264cf991f4","acronym":"FusionVAC22","url":"https://clinicaltrials.gov/study/NCT05937295","created_at":"2023-07-10T13:08:43.081Z","updated_at":"2024-07-02T16:35:35.247Z","phase":"Phase 1","brief_title":"FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition","source_id_and_acronym":"NCT05937295 - FusionVAC22","lead_sponsor":"University Hospital Tuebingen","biomarkers":" DNAJB1 • PRKACA","pipe":" | ","alterations":" DNAJB1-PRKACA fusion","tags":["DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • DNAJB1-PRKACA peptide vaccine • Fusion-VAC-XS15"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/26/2023","start_date":" 09/26/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-09-29"}]